{ "@context": "https://peptos.life/partners/affiliate-toolkit.json", "page": "https://peptos.life/partners/affiliate-toolkit", "canonical": "https://peptos.life/partners/affiliate-toolkit", "license": "CC BY 4.0 — reuse with attribution and a link back to peptos.life", "generated_from": "partner-toolkit.data.js", "last_reviewed": "2026-08-15", "mode": "WAITLIST", "laws": [ "Two-signal law: regulatory status and availability verdict are separate fields and are never merged into one sentence.", "No availability claim on any molecule not marked Available in /fda-tracker.json.", "\"Compounded, not FDA-approved\" appears in the content whenever a compounded product is named.", "Zero dosing content: no amounts, units, schedules, titration, reconstitution or cycling anywhere in this payload.", "A PCAC recommendation is advice to FDA that starts rulemaking. Not approval, not authorization to compound, not availability.", "No outcome guarantees, superlatives or unsourced figures.", "rel=\"sponsored\" on every generated affiliate link, without exception.", "WAITLIST MODE: no price is a live offer, nothing is purchasable, every sellable-intent CTA terminates at /waitlist." ], "status_source": { "note": "This file contains NO molecule status. Every status, verdict and regulatory pill must be read live from the feeds below.", "tracker": "https://peptos.life/fda-tracker.json", "molecules_feed": "https://peptos.life/embed/molecules.json", "search_index": "https://peptos.life/embed/search-index.json", "monograph_manifest": "https://peptos.life/embed/monographs.json" }, "utm_convention": "?partner={id}&utm_source={channel}&utm_medium=affiliate&utm_campaign={campaign}", "channels": [ { "id": "short_video", "label": "Short video (Reels / TikTok / Shorts)", "utm_source": "short-video", "disclosure_key": "Short video (Reels / TikTok / Shorts)" }, { "id": "long_video", "label": "Long video (YouTube)", "utm_source": "long-video", "disclosure_key": "Long video (YouTube)" }, { "id": "written", "label": "Written post (LinkedIn / X / blog)", "utm_source": "written", "disclosure_key": "Written post (LinkedIn / X / blog)" }, { "id": "email", "label": "Email", "utm_source": "email", "disclosure_key": "Email" }, { "id": "story", "label": "Story / ephemeral", "utm_source": "story", "disclosure_key": "Story / ephemeral" } ], "disclosures": [ { "fmt": "Short video (Reels / TikTok / Shorts)", "text": "#ad — paid partnership with Peptós.LIFE", "note": "On screen, in the first three seconds, and said out loud. Not only in the caption, and never only in a pinned comment." }, { "fmt": "Long video (YouTube)", "text": "Paid partnership with Peptós.LIFE. I earn a commission if you use my link.", "note": "Spoken in the first thirty seconds AND on screen, plus the platform's own paid-promotion toggle. The description alone is not disclosure." }, { "fmt": "Written post (LinkedIn / X / blog)", "text": "Disclosure: paid partnership with Peptós.LIFE. I earn a commission on referrals through my link.", "note": "Above the link and above the fold — before the reader has to click \"see more\"." }, { "fmt": "Email", "text": "This email contains an affiliate link to Peptós.LIFE. I earn a commission if you sign up through it.", "note": "In the body, before the link. Not in the template footer." }, { "fmt": "Story / ephemeral", "text": "#ad · paid partnership with Peptós.LIFE", "note": "On every frame that carries the link, not only the first. Frames get skipped." } ], "banned_terms": [ { "term": "available", "rule": "Availability", "fix": "Say what the rule currently says and link the tracker. Access is a separate signal." }, { "term": "availability", "rule": "Availability", "fix": "Name the regulatory state instead, and let the tracker carry access." }, { "term": "in stock", "rule": "Availability", "fix": "There is no stock language on this site. Route to the tracker or the waitlist." }, { "term": "back in stock", "rule": "Availability", "fix": "Delete it. Nothing on the gated list is coming back on a date we can name." }, { "term": "back soon", "rule": "Availability", "fix": "Delete it. We do not know, and a date we invent is a claim." }, { "term": "buy", "rule": "Availability", "fix": "Nothing is transactable. Use “see what a clinician-built protocol looks like”." }, { "term": "order", "rule": "Availability", "fix": "Nothing is transactable. Route the intent to /waitlist." }, { "term": "shop", "rule": "Availability", "fix": "Nothing is transactable. Route the intent to /waitlist." }, { "term": "cart", "rule": "Availability", "fix": "There is no cart. Remove the commerce framing entirely." }, { "term": "dm me", "rule": "Availability", "fix": "Sourcing framing. Link the tracker page instead." }, { "term": "legal now", "rule": "Legality", "fix": "Say which rule changed and when, and link the docket." }, { "term": "now legal", "rule": "Legality", "fix": "Say which rule changed and when, and link the docket." }, { "term": "fda-approved", "rule": "FDA approval", "fix": "Compounded products are not FDA-approved. Say “compounded, not FDA-approved”." }, { "term": "fda approved", "rule": "FDA approval", "fix": "Compounded products are not FDA-approved. Say “compounded, not FDA-approved”." }, { "term": "approved by the fda", "rule": "FDA approval", "fix": "A committee recommendation is not approval. Say “recommended; rulemaking pending”." }, { "term": "guaranteed", "rule": "Outcome claims", "fix": "No biological result can be guaranteed. Describe the method, not the outcome." }, { "term": "guarantee", "rule": "Outcome claims", "fix": "No biological result can be guaranteed. Describe the method, not the outcome." }, { "term": "cure", "rule": "Outcome claims", "fix": "Nothing here cures anything. Describe what the protocol is built to support." }, { "term": "reverse aging", "rule": "Outcome claims", "fix": "Unsupportable. “Biological-age measurement” is the honest version." }, { "term": "anti-aging", "rule": "Outcome claims", "fix": "Use “longevity” or “biological age”, which are what we actually measure." }, { "term": "miracle", "rule": "Outcome claims", "fix": "Superlative. Delete it." }, { "term": "a number with a unit (250mcg, 5 mg, 500iu)", "rule": "Dosing", "pattern": "[0-9]\\s*(mg|mcg|ug|iu|ml|units?)([^A-Za-z]|$)", "fix": "Zero dosing content. Remove the amount and the unit together — there is no compliant way to publish a number attached to a unit." }, { "term": "mg", "rule": "Dosing", "pattern": "(^|[^A-Za-z])mg([^A-Za-z]|$)", "fix": "Zero dosing content. Remove the unit and the amount entirely." }, { "term": "mcg", "rule": "Dosing", "pattern": "(^|[^A-Za-z])mcg([^A-Za-z]|$)", "fix": "Zero dosing content. Remove the unit and the amount entirely." }, { "term": "ug", "rule": "Dosing", "pattern": "(^|[^A-Za-z])ug([^A-Za-z]|$)", "fix": "Zero dosing content. Remove the unit and the amount entirely." }, { "term": "iu", "rule": "Dosing", "pattern": "(^|[^A-Za-z])iu([^A-Za-z]|$)", "fix": "Zero dosing content. Remove the unit and the amount entirely." }, { "term": "ml", "rule": "Dosing", "pattern": "(^|[^A-Za-z])ml([^A-Za-z]|$)", "fix": "Zero dosing content. Remove the unit and the amount entirely." }, { "term": "dose", "rule": "Dosing", "fix": "A clinician sets any dose. Do not name, imply, or range one." }, { "term": "dosing", "rule": "Dosing", "fix": "A clinician sets any dose. Do not name, imply, or range one." }, { "term": "protocol", "rule": "Dosing", "fix": "Only in the phrase “clinician-built protocol”, never as an amount or schedule you describe." }, { "term": "cycle", "rule": "Dosing", "fix": "Cycling is dosing content. Remove it." }, { "term": "titrate", "rule": "Dosing", "fix": "Titration is dosing content. Remove it." }, { "term": "reconstitute", "rule": "Dosing", "fix": "Reconstitution is dosing content. Remove it." } ], "proof_cues": [ "Named clinicians", "Third-party tested", "Every ingredient disclosed", "All-in pricing, no add-ons" ], "waitlist_note": "Consults open soon. This routes to the founding list.", "payout": { "mode": "WAITLIST", "qualifying_action_now": "Founding-list signup at https://peptos.life/waitlist", "attribution_scope": "Site-wide, including the FDA Tracker and Knowledge Base pages", "cookie_window_days": "[N]", "cpa_usd": "[N]", "note": "Rates are set in the partner agreement. No figure is published because none has been set." }, "lanes": [ { "id": "womens", "label": "Women's longevity", "door": "/womens-longevity", "persona": "Glow Gwen · Reset Renee", "note": "Perimenopause and menopause, 40–64. The highest-intent, least-served audience on the site." }, { "id": "metabolic", "label": "Metabolic / weight", "door": "/metabolic-reset", "persona": "Reset Renee · Maintain Mara", "note": "The commodity door. Acquire here, differentiate on the path, not the molecule." }, { "id": "recovery", "label": "Recovery", "door": "/recovery", "persona": "Recover Rex", "note": "Where the search volume is unsellable and the deferred attribution pays anyway." }, { "id": "longevity", "label": "Longevity / energy", "door": "/longevity", "persona": "Optimize Omar", "note": "Measurement-led. This reader wants a method before a molecule." }, { "id": "sexual", "label": "Sexual health", "door": "/sexual-health", "persona": "Drive Dan", "note": "High intent, low tolerance for hype. Plain language outperforms every time." } ], "kits": [ { "slug": "/weight-at-45-wont-move", "title": "Weight at 45 won't move", "lane": "metabolic", "intent_type": "symptom", "persona": "Reset Renee", "search_intent": "informational, high-frustration, pre-solution", "keyword_cluster": [ "why can't I lose weight at 45", "perimenopause weight gain", "metabolism after 40" ], "the_reader": "A woman in her mid-forties who has just typed her own frustration into Google after the thing that worked at 35 stopped working.", "why_it_converts": "It moves her from “I lost discipline” to “my physiology changed” — which is the belief that makes a clinician visit reasonable instead of shameful.", "hooks": [ { "channel": "short_video", "text": "The advice that worked at 35 is not failing you because you stopped trying. Your hormonal baseline moved. Here is what changed and what a clinician actually looks at." }, { "channel": "long_video", "text": "Why calorie maths stops predicting the scale in your forties — what shifts in perimenopause, what a clinician measures before recommending anything, and what nobody can promise you." }, { "channel": "written", "text": "Nothing about your effort changed at 45. Your baseline did. Here is the physiology, in plain language, and what a clinician-built path looks like from the first appointment." }, { "channel": "email_subject", "text": "The thing that worked at 35 stopped working. That is physiology, not willpower." } ], "say_this": [ "Perimenopause changes the metabolic baseline. That is a documented physiological shift, not a discipline problem.", "A clinician reviews your history and labs before recommending anything at all.", "Compounded medications used in this category are not FDA-approved." ], "never_this": [ "Any figure of pounds lost, or any timeframe attached to a result.", "“Finally works” / “the fix” / any framing that makes the page a promise.", "Naming a specific medication as something she can get today." ], "cta": { "compliant_text": "See what a clinician-built path actually looks like", "destination": "/weight-at-45-wont-move" }, "adjacent_molecules": [ "semaglutide", "tirzepatide" ], "gated_adjacency": [], "tracker_links": [ "/fda-tracker/semaglutide" ], "kb_links": [ "/knowledge-base" ], "required_disclosure_ref": "written", "widget_recommendation": "page_card", "notes": "The single strongest cold-traffic destination in the metabolic lane. Resist adding a number to the hook — the frustration is the hook." }, { "slug": "/exhausted-after-8-hours-sleep", "title": "Exhausted after eight hours of sleep", "lane": "longevity", "intent_type": "symptom", "persona": "Optimize Omar", "search_intent": "informational, symptom-first, no diagnosis yet", "keyword_cluster": [ "tired after 8 hours sleep", "why am I always exhausted", "fatigue not sleep deprivation" ], "the_reader": "Someone who has already fixed their sleep hygiene, still wakes tired, and has been told by a GP that their bloods are normal.", "why_it_converts": "It separates sleep quantity from cellular energy, which reframes “normal bloods” from a dead end into an incomplete panel.", "hooks": [ { "channel": "short_video", "text": "Eight hours and still flattened by 2pm? Sleep duration and cellular energy are two different problems. Only one of them is fixed by going to bed earlier." }, { "channel": "long_video", "text": "Normal bloodwork and permanent exhaustion: what a standard panel does not measure, what a longevity clinician adds, and why “normal” is a range, not a verdict." }, { "channel": "written", "text": "You fixed the sleep. You are still exhausted. That is worth investigating properly, and here is what a fuller workup actually includes." }, { "channel": "email_subject", "text": "Eight hours of sleep and still exhausted — what a standard panel misses" } ], "say_this": [ "Sleep duration and cellular energy production are different systems.", "A standard panel is a starting point, not a complete picture.", "Any recommendation follows a clinician review of your history and labs." ], "never_this": [ "Naming a molecule as the answer to fatigue.", "Any claim that a protocol restores energy.", "Suggesting the reader's doctor missed something out of incompetence." ], "cta": { "compliant_text": "See what a fuller workup includes", "destination": "/exhausted-after-8-hours-sleep" }, "adjacent_molecules": [ "nad", "b12" ], "gated_adjacency": [ "mots-c" ], "tracker_links": [ "/fda-tracker/nad" ], "kb_links": [ "/knowledge-base", "/peptides/how-we-grade" ], "required_disclosure_ref": "written", "widget_recommendation": "page_card", "notes": "MOTS-c gets named constantly in this niche and is gated. Use the status card, never a mention on its own." }, { "slug": "/recovery-slower-than-it-used-to-be", "title": "Recovery is slower than it used to be", "lane": "recovery", "intent_type": "symptom", "persona": "Recover Rex", "search_intent": "informational, performance-motivated", "keyword_cluster": [ "recovery slower after 40", "training soreness lasting days", "joint recovery age" ], "the_reader": "A lifter or endurance athlete in their late thirties to fifties whose recovery window has doubled and who is already reading peptide forums.", "why_it_converts": "It gives a forum-literate reader a source that separates what the evidence says from what he can actually get — which no forum does.", "hooks": [ { "channel": "short_video", "text": "If your recovery window doubled, you have probably already read the peptide threads. Here is the part those threads leave out: the regulatory status, which is a completely separate question from whether it works." }, { "channel": "long_video", "text": "The recovery peptides everyone names, graded on evidence, with each one's current regulatory position and what that does and does not mean for access." }, { "channel": "written", "text": "The recovery peptide conversation has two questions in it and they get merged constantly: what does the evidence show, and where does the rule currently stand. Here they are, separately." }, { "channel": "email_subject", "text": "The recovery peptide threads leave out the only part that matters" } ], "say_this": [ "Evidence grade and regulatory status are separate questions with separate answers.", "The committee recommended six of seven peptides in July 2026; a recommendation starts rulemaking, it is not approval and not access.", "You can read everything we have on a molecule without any of it being an offer." ], "never_this": [ "Any hint that BPC-157 or TB-500 can be obtained.", "Any dose, schedule, or “what I run”.", "“Coming back soon” — nobody knows the date." ], "cta": { "compliant_text": "See where each recovery peptide actually stands", "destination": "/recovery-slower-than-it-used-to-be" }, "adjacent_molecules": [], "gated_adjacency": [ "bpc-157", "tb-500" ], "tracker_links": [ "/fda-tracker/bpc-157", "/fda-tracker/tb-500" ], "kb_links": [ "/bpc-157-vs-tb-500", "/peptides/how-we-grade" ], "required_disclosure_ref": "written", "widget_recommendation": "status_card", "notes": "THE unsellable-demand page. Highest search volume in the category, zero sellable molecules. Attribution is deferred and site-wide — that is the whole play." }, { "slug": "/menopause-energy", "title": "Menopause energy", "lane": "womens", "intent_type": "symptom", "persona": "Glow Gwen", "search_intent": "informational, post-diagnosis, solution-seeking", "keyword_cluster": [ "menopause fatigue", "no energy menopause", "menopause brain fog energy" ], "the_reader": "A woman past the transition who has been told fatigue is simply what this is now, and has decided not to accept that.", "why_it_converts": "It treats her as the sharp, capable person she was, and says the loss is worth investigating rather than absorbing.", "hooks": [ { "channel": "short_video", "text": "“That's just menopause” is a description, not a diagnosis. It does not tell you which system is under-supported, and it is not a reason to stop asking." }, { "channel": "long_video", "text": "Menopause fatigue, taken seriously: what actually changes, what a clinician measures, and why being told it is normal is not the same as being told it is unfixable." }, { "channel": "written", "text": "You were capable, sharp and energetic. Being told that is over is not a clinical finding. Here is what a proper workup looks like." }, { "channel": "email_subject", "text": "“That's just menopause” is a description, not a diagnosis" } ], "say_this": [ "Symptoms are real, measurable, and worth investigating rather than absorbing.", "Named clinicians review every case before anything is recommended.", "Compounded medications are not FDA-approved." ], "never_this": [ "Vanity or before/after framing — this reader is reclaiming capability, not appearance.", "Any promise that energy returns.", "Positioning us as a replacement for her existing prescriber." ], "cta": { "compliant_text": "See how a clinician approaches menopause fatigue", "destination": "/menopause-energy" }, "adjacent_molecules": [ "nad", "b12" ], "gated_adjacency": [], "tracker_links": [ "/fda-tracker/nad" ], "kb_links": [ "/womens-longevity" ], "required_disclosure_ref": "written", "widget_recommendation": "page_card", "notes": "Casting and tone matter more here than on any other page. Reclamation, never vanity, never weight-shame." }, { "slug": "/perimenopause-weight", "title": "Perimenopause weight", "lane": "womens", "intent_type": "symptom", "persona": "Reset Renee", "search_intent": "informational, high-frustration", "keyword_cluster": [ "perimenopause weight gain", "belly fat perimenopause", "can't lose weight perimenopause" ], "the_reader": "A woman 42–52 watching her body composition change on the same routine she has run for a decade.", "why_it_converts": "It names the mechanism instead of prescribing more discipline, which is the only thing she has not already been told.", "hooks": [ { "channel": "short_video", "text": "Same food, same training, different body. That is not a discipline story. Here is what shifts in perimenopause and what a clinician looks at first." }, { "channel": "long_video", "text": "Perimenopausal body-composition change, explained properly: what moves, why the old routine stops mapping to the result, and what a clinician-led path involves." }, { "channel": "written", "text": "The routine did not stop working because you stopped caring. Here is the physiology, and what a clinician-built path actually involves." }, { "channel": "email_subject", "text": "Same routine, different body. Here is what actually changed." } ], "say_this": [ "Hormonal change alters body composition independently of intake and training.", "A clinician reviews labs and history before anything is recommended.", "Compounded medications are not FDA-approved." ], "never_this": [ "Any weight figure, any timeframe.", "Before/after imagery or framing.", "Naming a GLP-1 as the answer in the hook." ], "cta": { "compliant_text": "See the clinician-led path for perimenopause", "destination": "/perimenopause-weight" }, "adjacent_molecules": [ "semaglutide", "tirzepatide" ], "gated_adjacency": [], "tracker_links": [ "/fda-tracker/semaglutide" ], "kb_links": [ "/womens-longevity" ], "required_disclosure_ref": "written", "widget_recommendation": "page_card", "notes": "Highest-converting women's destination. Lead on the path, not the molecule." }, { "slug": "/post-ozempic-maintain", "title": "After the GLP-1: maintaining", "lane": "metabolic", "intent_type": "symptom", "persona": "Maintain Mara", "search_intent": "transactional-adjacent, post-treatment, anxious", "keyword_cluster": [ "what happens when I stop ozempic", "maintain weight after GLP-1", "GLP-1 rebound" ], "the_reader": "Someone approaching the end of a GLP-1 course who has read that the weight comes back and has no plan for the next phase.", "why_it_converts": "Nobody sold her the maintenance phase. Being the first to name it as a phase, with a method, is the whole conversion.", "hooks": [ { "channel": "short_video", "text": "The hard part of a GLP-1 is not starting it. It is the six months after, which almost nobody plans for and almost nobody sells you." }, { "channel": "long_video", "text": "What actually happens metabolically when a GLP-1 course ends, why the rebound is predictable, and what a maintenance phase involves when a clinician designs one." }, { "channel": "written", "text": "You were sold the loss. Nobody sold you the maintenance. That gap is where most of the result gets given back, and it is plannable." }, { "channel": "email_subject", "text": "Nobody planned your maintenance phase. That is where the result goes." } ], "say_this": [ "Maintenance is a distinct clinical phase with its own plan.", "Rebound after discontinuation is documented, not a personal failure.", "Any next step is set by a clinician who has reviewed your case." ], "never_this": [ "Fear-based framing about regaining everything.", "Any specific percentage of regain.", "Implying a maintenance product is purchasable today." ], "cta": { "compliant_text": "See what a maintenance phase involves", "destination": "/post-ozempic-maintain" }, "adjacent_molecules": [ "semaglutide", "tirzepatide" ], "gated_adjacency": [], "tracker_links": [ "/fda-tracker/semaglutide" ], "kb_links": [ "/metabolic-reset" ], "required_disclosure_ref": "written", "widget_recommendation": "page_card", "notes": "Warmest audience on the site — they have already paid for this category once." }, { "slug": "/gut-repair-after-glp1", "title": "Gut repair after a GLP-1", "lane": "metabolic", "intent_type": "symptom", "persona": "Maintain Mara", "search_intent": "informational, side-effect-driven", "keyword_cluster": [ "GLP-1 gut side effects", "nausea after semaglutide", "gut health after ozempic" ], "the_reader": "Someone tolerating real gastrointestinal side effects and searching for whether it settles or whether they should stop.", "why_it_converts": "Acknowledging the side effect honestly earns more trust than any benefit claim, because everyone else is minimising it.", "hooks": [ { "channel": "short_video", "text": "The gut side effects of a GLP-1 are not a rumour and they are not a reason to quietly stop taking it. They are a conversation to have with the clinician who prescribed it." }, { "channel": "long_video", "text": "Gastrointestinal effects on a GLP-1: what is expected, what is not, and why stopping without telling your prescriber is the worst version of managing it." }, { "channel": "written", "text": "Nobody warned you properly about the gut effects. Here is what is documented, and what to raise with your clinician before you make any change." }, { "channel": "email_subject", "text": "The GLP-1 gut side effects nobody prepped you for" } ], "say_this": [ "Gastrointestinal effects are documented and should be discussed with your prescriber.", "Do not change anything about a prescription on the basis of an article.", "Compounded medications are not FDA-approved." ], "never_this": [ "Naming KPV or any gut peptide as the solution — it is gated.", "Any suggestion to adjust or stop a prescription.", "Minimising the side effect to protect the category." ], "cta": { "compliant_text": "See what to raise with your clinician", "destination": "/gut-repair-after-glp1" }, "adjacent_molecules": [ "semaglutide" ], "gated_adjacency": [ "kpv" ], "tracker_links": [ "/fda-tracker/kpv" ], "kb_links": [ "/knowledge-base" ], "required_disclosure_ref": "written", "widget_recommendation": "status_card", "notes": "KPV is the temptation here and it is education-only. Embed the status card rather than naming it in prose." }, { "slug": "/glp1-energy", "title": "Energy on a GLP-1", "lane": "metabolic", "intent_type": "symptom", "persona": "Reset Renee", "search_intent": "informational, in-treatment", "keyword_cluster": [ "tired on semaglutide", "GLP-1 fatigue", "no energy on ozempic" ], "the_reader": "Someone currently on a GLP-1, losing weight, and feeling worse than before they started.", "why_it_converts": "It gives a name to a side effect she assumed was her fault, from a source that is not trying to talk her out of the drug.", "hooks": [ { "channel": "short_video", "text": "Losing the weight and feeling worse than you did before? Fatigue on a GLP-1 is a documented, discussable thing, not you being ungrateful." }, { "channel": "long_video", "text": "Fatigue during GLP-1 treatment: what is documented, what a clinician checks, and why intake changes underneath the drug matter more than most people are told." }, { "channel": "written", "text": "The scale is moving and you feel worse. That is a real, documented pattern and it belongs in a conversation with your clinician, not in a forum." }, { "channel": "email_subject", "text": "Losing weight and feeling worse — the pattern nobody names" } ], "say_this": [ "Fatigue during treatment is documented and worth raising with your prescriber.", "Nutritional intake often changes substantially during treatment.", "A clinician reviews the whole picture before anything is added." ], "never_this": [ "Positioning any product as the energy fix.", "Advising anyone to stop or change a prescription.", "Any dose or schedule reference." ], "cta": { "compliant_text": "See what a clinician checks first", "destination": "/glp1-energy" }, "adjacent_molecules": [ "nad", "b12", "semaglutide" ], "gated_adjacency": [], "tracker_links": [ "/fda-tracker/nad" ], "kb_links": [ "/knowledge-base" ], "required_disclosure_ref": "written", "widget_recommendation": "page_card", "notes": "In-treatment audience. Never write anything that reads as advice to alter a live prescription." }, { "slug": "/microdose-glp1", "title": "Microdose GLP-1", "lane": "metabolic", "intent_type": "symptom", "persona": "Maintain Mara", "search_intent": "informational, self-disqualified", "keyword_cluster": [ "microdose GLP-1", "low dose semaglutide", "GLP-1 without obesity" ], "the_reader": "Someone with a BMI in the low-to-normal band who has been told they do not qualify for a full-dose programme and assumes that is the end of it.", "why_it_converts": "It is the disqualified-lead save: the reader who was told no everywhere else finds a door that is still clinician-gated but not closed.", "hooks": [ { "channel": "short_video", "text": "Told you do not qualify for a weight-loss programme? That is one door, not the whole building. There is a separate clinician-gated path and it starts with a different question." }, { "channel": "long_video", "text": "Why full-dose weight-loss programmes turn people away, what the alternative clinical route involves, and why both of them still end with a clinician deciding." }, { "channel": "written", "text": "Being told you do not qualify is not the end of the conversation. It routes you to a different clinical question, which is the one this page is about." }, { "channel": "email_subject", "text": "Told you do not qualify? That is one door, not the building." } ], "say_this": [ "This is a separate clinical route with its own eligibility, decided by a clinician.", "Compounded medications are not FDA-approved.", "Eligibility is assessed, never assumed." ], "never_this": [ "Any amount, any comparison of amounts, any “lower dose” framing with a number attached.", "Suggesting a reader can choose their own route.", "Any availability claim." ], "cta": { "compliant_text": "See which clinical route applies to you", "destination": "/microdose-glp1" }, "adjacent_molecules": [ "semaglutide", "tirzepatide" ], "gated_adjacency": [], "tracker_links": [ "/fda-tracker/semaglutide" ], "kb_links": [ "/metabolic-reset" ], "required_disclosure_ref": "written", "widget_recommendation": "page_card", "notes": "The word “microdose” is in our page title but is NOT licence to describe amounts. Never quantify anything here." }, { "slug": "/metabolic-reset", "title": "Metabolic Reset", "lane": "metabolic", "intent_type": "symptom", "persona": "Reset Renee", "search_intent": "brand-adjacent, programme-seeking", "keyword_cluster": [ "metabolic reset programme", "clinician led weight programme", "medical weight management" ], "the_reader": "Someone who has decided to do this properly and is now comparing programmes rather than molecules.", "why_it_converts": "It is the only page that answers “what am I actually buying into” with a named process instead of a product list.", "hooks": [ { "channel": "short_video", "text": "Stop comparing medications and start comparing programmes. The molecule is the commodity. What sits around it is the entire difference in outcome." }, { "channel": "long_video", "text": "What a clinician-led metabolic programme includes end to end, and the specific questions to ask any provider before you commit to one." }, { "channel": "written", "text": "Everyone is selling the same molecules. The difference is the path around them — the clinician, the monitoring, the maintenance phase, the pricing you can actually read." }, { "channel": "email_subject", "text": "The molecule is the commodity. The path is the difference." } ], "say_this": [ "Metabolic Reset is our named programme, not a proprietary molecule.", "Named clinicians, third-party testing, every ingredient disclosed, all-in pricing.", "Compounded medications are not FDA-approved." ], "never_this": [ "Describing the programme as proprietary IP or trademarked technology.", "Any outcome figure.", "Any purchase framing while consults are not open." ], "cta": { "compliant_text": "See what the programme includes", "destination": "/metabolic-reset" }, "adjacent_molecules": [ "semaglutide", "tirzepatide", "liraglutide" ], "gated_adjacency": [], "tracker_links": [ "/fda-tracker" ], "kb_links": [ "/how-to-spot-a-legit-provider" ], "required_disclosure_ref": "written", "widget_recommendation": "page_card", "notes": "The metabolic lane door. Use it as the destination when a reader is comparing rather than searching a symptom." }, { "slug": "/mens-weight-loss", "title": "Men's weight loss", "lane": "metabolic", "intent_type": "symptom", "persona": "Optimize Omar", "search_intent": "transactional-adjacent, price-comparing", "keyword_cluster": [ "mens weight loss programme", "GLP-1 for men", "medical weight loss men" ], "the_reader": "A man comparing three telehealth offers on price who has not yet noticed that only one of them shows the ongoing figure.", "why_it_converts": "The transparency wedge: showing promo and ongoing pricing plainly beats every competitor's first-month headline.", "hooks": [ { "channel": "short_video", "text": "Three providers, three first-month prices, and only one of them tells you what month four costs. That gap is the entire comparison." }, { "channel": "long_video", "text": "How to compare medical weight-loss offers properly: the promotional figure, the ongoing figure, what is bundled, and the questions that expose the difference." }, { "channel": "written", "text": "Compare the ongoing figure, not the first-month one. Here is how the offers actually stack up when you read them straight." }, { "channel": "email_subject", "text": "Everyone advertises month one. Ask what month four costs." } ], "say_this": [ "Reference figures are as-of-date and are not a live offer while consults are not open.", "All-in pricing with nothing added at checkout.", "Compounded medications are not FDA-approved." ], "never_this": [ "Quoting any figure as a live, purchasable price.", "Any guaranteed-loss claim.", "Naming a competitor as dishonest — describe the pattern, not the company." ], "cta": { "compliant_text": "See the pricing written out in full", "destination": "/mens-weight-loss" }, "adjacent_molecules": [ "semaglutide", "tirzepatide" ], "gated_adjacency": [], "tracker_links": [ "/fda-tracker/tirzepatide" ], "kb_links": [ "/men", "/how-to-spot-a-legit-provider" ], "required_disclosure_ref": "written", "widget_recommendation": "page_card", "notes": "WAITLIST MODE applies hardest here. Any figure is a reference, never an offer." }, { "slug": "/womens-weight-loss", "title": "Women's weight loss", "lane": "womens", "intent_type": "symptom", "persona": "Reset Renee", "search_intent": "transactional-adjacent, trust-led", "keyword_cluster": [ "womens weight loss programme", "GLP-1 for women", "weight loss perimenopause programme" ], "the_reader": "A woman who has been dismissed by at least two providers and is deciding whether this one will take her seriously.", "why_it_converts": "She is not comparing price, she is screening for whether she will be dismissed again. Proof cues outperform offers here.", "hooks": [ { "channel": "short_video", "text": "If you have been told to just eat less and move more by two different clinicians, the problem is the intake, not you. Here is what a proper one asks." }, { "channel": "long_video", "text": "What a women's metabolic programme should include, why hormonal context changes the plan, and the questions that tell you whether a provider has actually thought about women." }, { "channel": "written", "text": "She was dismissed twice before she got here. Here is what a programme built for the hormonal context actually looks like." }, { "channel": "email_subject", "text": "Dismissed twice? Here is what a proper intake asks." } ], "say_this": [ "Hormonal context changes the clinical plan and should change the intake.", "Named clinicians. Every ingredient disclosed.", "Compounded medications are not FDA-approved." ], "never_this": [ "Weight-shame framing of any kind.", "Any figure or timeframe for a result.", "Vanity framing — this is capability, not appearance." ], "cta": { "compliant_text": "See what a proper intake asks", "destination": "/womens-weight-loss" }, "adjacent_molecules": [ "semaglutide", "tirzepatide" ], "gated_adjacency": [], "tracker_links": [ "/fda-tracker/semaglutide" ], "kb_links": [ "/womens-longevity" ], "required_disclosure_ref": "written", "widget_recommendation": "page_card", "notes": "Casting per the FEMtech brief: real women 45–58, inclusive by default, reclamation not vanity." }, { "slug": "/biological-age", "title": "Biological age", "lane": "longevity", "intent_type": "symptom", "persona": "Optimize Omar", "search_intent": "informational, measurement-curious", "keyword_cluster": [ "biological age test", "epigenetic age", "how old is my body really" ], "the_reader": "A measurement-first reader who wants a number before they want an intervention, and who is sceptical of the whole category.", "why_it_converts": "It leads with method and limitations, which is exactly the register a sceptic needs before they will consider anything else.", "hooks": [ { "channel": "short_video", "text": "Biological age is a measurement with real limitations, not a score to beat. Here is what the tests actually measure and what they do not." }, { "channel": "long_video", "text": "Biological-age testing, honestly: what the major methods measure, where they disagree, what a result can reasonably change, and what it cannot." }, { "channel": "written", "text": "Before any intervention, a measurement — and before that measurement, an honest account of what it can and cannot tell you." }, { "channel": "email_subject", "text": "Biological age: what the test measures, and what it does not" } ], "say_this": [ "These are measurements with documented limitations, not verdicts.", "We publish how we grade evidence, including where it is weak.", "Nothing here reverses anything." ], "never_this": [ "“Reverse aging” or “turn back the clock” in any form.", "Any age-reduction figure.", "Presenting a measurement as an outcome." ], "cta": { "compliant_text": "See how the measurements actually work", "destination": "/biological-age" }, "adjacent_molecules": [ "nad", "rapamycin" ], "gated_adjacency": [ "epitalon" ], "tracker_links": [ "/fda-tracker/nad" ], "kb_links": [ "/peptides/how-we-grade" ], "required_disclosure_ref": "written", "widget_recommendation": "status_card", "notes": "The “reverse aging” phrase is the most common violation on this page. It is banned outright." }, { "slug": "/daily-performance", "title": "Daily performance", "lane": "longevity", "intent_type": "symptom", "persona": "Optimize Omar", "search_intent": "informational, optimisation-minded", "keyword_cluster": [ "cognitive performance supplements", "daily energy protocol", "focus and recovery stack" ], "the_reader": "Someone already running a stack from podcasts and forums, looking for a source that grades rather than sells.", "why_it_converts": "It grades what he is already taking, which is a service, not a pitch — and the grading is what makes the next click credible.", "hooks": [ { "channel": "short_video", "text": "Half the things in your stack have one small human trial behind them and half have none. Here is the grading, including the parts where the evidence is thin." }, { "channel": "long_video", "text": "Grading the common daily-performance stack: what has controlled human evidence, what has animal data only, and what has a podcast episode and nothing else." }, { "channel": "written", "text": "A graded read of the daily-performance stack, with the weak evidence labelled as weak. That is the whole value." }, { "channel": "email_subject", "text": "Your stack, graded — including the parts with no evidence" } ], "say_this": [ "We publish our grading method, including where the evidence is weak or absent.", "Evidence grade is a separate signal from regulatory status.", "Nothing on this page is a recommendation to take anything." ], "never_this": [ "Naming Semax or any gated nootropic peptide as obtainable.", "Any dose, stack schedule, or “what I take”.", "Superlatives about any single molecule." ], "cta": { "compliant_text": "See the grading method", "destination": "/daily-performance" }, "adjacent_molecules": [ "nad" ], "gated_adjacency": [ "semax", "mots-c" ], "tracker_links": [ "/fda-tracker/semax" ], "kb_links": [ "/peptides/how-we-grade", "/stacks" ], "required_disclosure_ref": "written", "widget_recommendation": "status_card", "notes": "Forum-literate audience. The credibility comes from labelling weak evidence as weak." }, { "slug": "/longevity-stack", "title": "Longevity stack", "lane": "longevity", "intent_type": "symptom", "persona": "Optimize Omar", "search_intent": "informational, comparison-stage", "keyword_cluster": [ "longevity stack", "best longevity protocol", "what to take for longevity" ], "the_reader": "Someone assembling a long-term plan and trying to work out which of the twelve things they have read about are actually supported.", "why_it_converts": "It replaces a shopping list with a method for deciding, which is more useful and far more defensible.", "hooks": [ { "channel": "short_video", "text": "There is no single longevity stack. There is a method for deciding what belongs in yours, and it starts with a measurement, not a molecule." }, { "channel": "long_video", "text": "Building a longevity plan from evidence rather than from podcasts: how to grade a claim, how to sequence, and what regulatory status has to do with any of it." }, { "channel": "written", "text": "Not a shopping list. A method for deciding what belongs in a long-term plan, and how to tell when the evidence is not there yet." }, { "channel": "email_subject", "text": "There is no single longevity stack. There is a method." } ], "say_this": [ "Sequencing and measurement come before any molecule.", "Every claim carries an evidence grade and a separate regulatory status.", "A clinician reviews the whole picture before recommending anything." ], "never_this": [ "Publishing a stack as a prescription.", "Any dose or ordering-by-amount.", "Naming a gated peptide as part of an obtainable stack." ], "cta": { "compliant_text": "See how a long-term plan is built", "destination": "/longevity-stack" }, "adjacent_molecules": [ "nad", "rapamycin" ], "gated_adjacency": [ "epitalon", "mots-c" ], "tracker_links": [ "/fda-tracker" ], "kb_links": [ "/stacks", "/peptides/how-we-grade" ], "required_disclosure_ref": "written", "widget_recommendation": "kb_search", "notes": "Best destination for the KB search widget — this reader arrives with a molecule name already in mind." }, { "slug": "/semaglutide", "title": "Semaglutide", "lane": "metabolic", "intent_type": "product", "persona": "Reset Renee", "search_intent": "high-intent, comparison and safety", "keyword_cluster": [ "compounded semaglutide", "semaglutide vs ozempic", "is compounded semaglutide safe" ], "the_reader": "Someone who already knows the molecule name and is now trying to work out whether the compounded version is legitimate.", "why_it_converts": "The FDA-approval distinction, stated plainly, is what converts a suspicious reader — because everyone else is blurring it.", "hooks": [ { "channel": "short_video", "text": "Compounded semaglutide is not FDA-approved. The branded versions are. Those are two different regulatory things and anyone blurring them is telling you something." }, { "channel": "long_video", "text": "Compounded versus branded semaglutide: the regulatory difference, what compounding pharmacies are and are not permitted to do, and the questions that separate a legitimate provider from a storefront." }, { "channel": "written", "text": "Compounded semaglutide is not FDA-approved, and any provider who lets you believe otherwise has told you what kind of provider they are." }, { "channel": "email_subject", "text": "Compounded semaglutide is not FDA-approved. Here is what that means." } ], "say_this": [ "Compounded semaglutide is not FDA-approved; the branded products are a different regulatory category.", "Third-party tested, every ingredient disclosed, named pharmacy.", "Regulatory status and access are separate signals — the tracker shows both." ], "never_this": [ "“FDA-approved” attached to the compounded product in any construction.", "Any dose, titration schedule, or reconstitution note.", "Any supply or availability promise — the shortage-exception picture is moving." ], "cta": { "compliant_text": "See the regulatory position and the testing", "destination": "/semaglutide" }, "adjacent_molecules": [ "semaglutide" ], "gated_adjacency": [], "tracker_links": [ "/fda-tracker/semaglutide" ], "kb_links": [ "/503a-vs-503b", "/how-to-spot-a-legit-provider" ], "required_disclosure_ref": "written", "widget_recommendation": "status_card", "notes": "Most regulatorily exposed page on the site. The FDA-approval line is not optional and not a footnote." }, { "slug": "/tirzepatide", "title": "Tirzepatide", "lane": "metabolic", "intent_type": "product", "persona": "Reset Renee", "search_intent": "high-intent, comparison", "keyword_cluster": [ "compounded tirzepatide", "tirzepatide vs semaglutide", "dual agonist weight loss" ], "the_reader": "A reader comparing the two molecules who has been told tirzepatide is simply better and wants to know if that is true.", "why_it_converts": "It answers the comparison honestly, including where the comparison does not hold, which is rarer than it should be.", "hooks": [ { "channel": "short_video", "text": "Tirzepatide and semaglutide are not the same mechanism, and “better” depends on which trial you are quoting and which population it enrolled." }, { "channel": "long_video", "text": "Tirzepatide versus semaglutide on the evidence: the mechanistic difference, what the head-to-head data shows, and where the comparison stops being meaningful." }, { "channel": "written", "text": "A straight comparison of the two molecules, including the parts where the honest answer is that it depends." }, { "channel": "email_subject", "text": "Tirzepatide vs semaglutide: what the comparison actually shows" } ], "say_this": [ "Compounded tirzepatide is not FDA-approved.", "Trial averages describe populations, never predict individuals.", "A clinician decides which molecule, if any, applies to you." ], "never_this": [ "Any percentage or pounds figure presented as what the reader will lose.", "Any dose or titration.", "Any supply promise." ], "cta": { "compliant_text": "See how the two molecules compare", "destination": "/tirzepatide" }, "adjacent_molecules": [ "tirzepatide", "semaglutide" ], "gated_adjacency": [], "tracker_links": [ "/fda-tracker/tirzepatide" ], "kb_links": [ "/503a-vs-503b" ], "required_disclosure_ref": "written", "widget_recommendation": "status_card", "notes": "If you cite a trial figure, name the trial and say it is an average." }, { "slug": "/nad", "title": "NAD+", "lane": "longevity", "intent_type": "product", "persona": "Optimize Omar", "search_intent": "informational to transactional", "keyword_cluster": [ "NAD+ injection", "NAD IV vs injection", "does NAD+ work" ], "the_reader": "Someone who has seen NAD+ marketed at clinic prices and wants to know whether the evidence justifies it.", "why_it_converts": "It is one of the few green-verdict molecules with real demand, so the honest evidence read and the access answer point the same way.", "hooks": [ { "channel": "short_video", "text": "NAD+ has more marketing behind it than evidence in front of it. Here is what is actually established and what is still open." }, { "channel": "long_video", "text": "NAD+ examined properly: the mechanism, what human data exists, what the clinic pricing is actually buying, and where the honest uncertainty sits." }, { "channel": "written", "text": "What is established about NAD+, what is extrapolated from animal work, and what the clinic price tag is actually paying for." }, { "channel": "email_subject", "text": "NAD+: separating the mechanism from the marketing" } ], "say_this": [ "Evidence grade is published, including where human data is limited.", "Regulatory status and access are separate signals.", "Compounded medications are not FDA-approved." ], "never_this": [ "Energy or anti-aging outcome promises.", "Any dose, frequency, or infusion schedule.", "Presenting mechanism as if it were outcome." ], "cta": { "compliant_text": "See the evidence and the pricing written out", "destination": "/nad" }, "adjacent_molecules": [ "nad" ], "gated_adjacency": [], "tracker_links": [ "/fda-tracker/nad" ], "kb_links": [ "/nad-cost", "/peptides/how-we-grade" ], "required_disclosure_ref": "written", "widget_recommendation": "status_card", "notes": "Pair with /nad-cost — the price-transparency page is what closes this reader." }, { "slug": "/nad-cost", "title": "What NAD+ actually costs", "lane": "longevity", "intent_type": "product", "persona": "Optimize Omar", "search_intent": "commercial investigation", "keyword_cluster": [ "NAD+ cost", "NAD IV price", "how much is NAD therapy" ], "the_reader": "Someone who has been quoted a clinic price and is checking whether it is normal before booking.", "why_it_converts": "Price transparency in a category built on opaque quotes is the entire differentiator, and this page is where it is provable.", "hooks": [ { "channel": "short_video", "text": "Clinic quotes for the same thing vary by multiples, and almost nobody publishes the number. Here it is, written out, with what is included." }, { "channel": "long_video", "text": "What NAD+ actually costs across delivery routes, why the quotes vary so widely, and what is and is not included in each format." }, { "channel": "written", "text": "Published pricing with the ongoing figure shown next to the promotional one. That comparison is the whole point of the page." }, { "channel": "email_subject", "text": "What NAD+ actually costs, written out" } ], "say_this": [ "Figures are reference figures as of a stated date, not a live offer while consults are not open.", "Promotional and ongoing figures are shown together, both plainly.", "All-in pricing, nothing added at checkout." ], "never_this": [ "Presenting any figure as purchasable today.", "“Cheapest” or any price superlative.", "Implying a competitor is overcharging — show the range, name nobody." ], "cta": { "compliant_text": "See the pricing written out in full", "destination": "/nad-cost" }, "adjacent_molecules": [ "nad" ], "gated_adjacency": [], "tracker_links": [ "/fda-tracker/nad" ], "kb_links": [ "/nad" ], "required_disclosure_ref": "written", "widget_recommendation": "page_card", "notes": "WAITLIST MODE: every figure is a dated reference. Say so in the same sentence as the number." }, { "slug": "/sildenafil", "title": "Sildenafil", "lane": "sexual", "intent_type": "product", "persona": "Drive Dan", "search_intent": "high-intent, privacy-sensitive", "keyword_cluster": [ "sildenafil online", "generic viagra telehealth", "ED treatment online" ], "the_reader": "A man who has decided to do something about it and wants the least embarrassing legitimate route.", "why_it_converts": "Plain, unembarrassed clinical language converts here. Every euphemism costs trust.", "hooks": [ { "channel": "short_video", "text": "This is a prescription medicine with a long safety record, handled by a clinician. The awkward part is the marketing, not the medicine." }, { "channel": "long_video", "text": "How the online ED route actually works: what the clinician reviews, why the intake questions matter medically, and what separates a legitimate provider from a storefront." }, { "channel": "written", "text": "A plain account of the medicine, the intake, and the pricing, with no euphemism anywhere in it." }, { "channel": "email_subject", "text": "The awkward part is the marketing, not the medicine" } ], "say_this": [ "Prescription medicine, clinician-reviewed intake, named pharmacy.", "Intake questions are medical screening, not paperwork.", "Reference pricing only while consults are not open." ], "never_this": [ "Performance superlatives or outcome guarantees.", "Any dose or timing instruction.", "Any framing that skips the clinical review." ], "cta": { "compliant_text": "See how the clinical route works", "destination": "/sildenafil" }, "adjacent_molecules": [], "gated_adjacency": [ "pt-141" ], "tracker_links": [ "/fda-tracker" ], "kb_links": [ "/ed-treatment", "/sexual-health" ], "required_disclosure_ref": "written", "widget_recommendation": "page_card", "notes": "PT-141 gets named in this niche constantly and is gated. Do not bring it into the hook." }, { "slug": "/tadalafil", "title": "Tadalafil", "lane": "sexual", "intent_type": "product", "persona": "Drive Dan", "search_intent": "high-intent, comparison", "keyword_cluster": [ "tadalafil vs sildenafil", "cialis online", "which ED medication" ], "the_reader": "A reader comparing the two molecules on duration and side-effect profile before choosing.", "why_it_converts": "The comparison is genuinely useful and genuinely clinical, which makes the clinician gate feel like a feature rather than friction.", "hooks": [ { "channel": "short_video", "text": "The two common ED medicines differ in duration and side-effect profile. Which one suits you is a clinical question with a real answer." }, { "channel": "long_video", "text": "Tadalafil and sildenafil compared on the clinical parameters that actually differ, and why the choice belongs with a prescriber rather than a comparison table." }, { "channel": "written", "text": "A clinical comparison of the two, with the honest conclusion that the choice depends on your history." }, { "channel": "email_subject", "text": "Tadalafil vs sildenafil: the differences that actually matter" } ], "say_this": [ "The clinical difference is real and the choice belongs with a prescriber.", "Both are prescription medicines with long safety records.", "Reference pricing only while consults are not open." ], "never_this": [ "Any dose or timing.", "Any performance claim.", "Recommending one over the other as general advice." ], "cta": { "compliant_text": "See the clinical comparison", "destination": "/tadalafil" }, "adjacent_molecules": [], "gated_adjacency": [], "tracker_links": [ "/fda-tracker" ], "kb_links": [ "/ed-treatment" ], "required_disclosure_ref": "written", "widget_recommendation": "page_card", "notes": "Cleanest destination in the sexual-health lane — no gated adjacency at all." }, { "slug": "/daily-tadalafil", "title": "Daily tadalafil", "lane": "sexual", "intent_type": "product", "persona": "Drive Dan", "search_intent": "high-intent, already-informed", "keyword_cluster": [ "daily tadalafil", "low dose daily cialis", "tadalafil every day" ], "the_reader": "Someone who has already used the on-demand version and is asking whether the daily approach suits them better.", "why_it_converts": "An informed reader asking a specific clinical question converts on a specific clinical answer, not on a pitch.", "hooks": [ { "channel": "short_video", "text": "On-demand and daily are two different clinical approaches with different reasons behind them. Which applies to you is a prescriber's call." }, { "channel": "long_video", "text": "The daily approach explained: why a clinician might choose it, what monitoring it involves, and who it is not appropriate for." }, { "channel": "written", "text": "The clinical reasoning behind the daily approach, including who it is not for." }, { "channel": "email_subject", "text": "Daily or on-demand? The clinical reasoning, plainly." } ], "say_this": [ "Two clinical approaches, chosen by a prescriber after review.", "Suitability depends on your history and current medicines.", "Reference pricing only while consults are not open." ], "never_this": [ "Any amount attached to the word “daily”.", "Any performance or frequency claim.", "Presenting the daily route as universally better." ], "cta": { "compliant_text": "See which approach a clinician would consider", "destination": "/daily-tadalafil" }, "adjacent_molecules": [], "gated_adjacency": [], "tracker_links": [ "/fda-tracker" ], "kb_links": [ "/ed-treatment", "/sexual-health" ], "required_disclosure_ref": "written", "widget_recommendation": "page_card", "notes": "“Daily” describes a clinical approach here, never an amount. Never quantify." } ], "secondary_tier": [ { "slug": "/treatments", "title": "Treatments hub", "lane": "metabolic", "angle": "The full catalogue, one page, with each entry's own status.", "caution": "Hub page — never summarise multiple molecules into one status sentence." }, { "slug": "/ed-treatment", "title": "ED treatment hub", "lane": "sexual", "angle": "The route, the review, the pricing, no euphemism.", "caution": "No performance claims of any kind." }, { "slug": "/womens-longevity", "title": "Women's longevity hub", "lane": "womens", "angle": "The door for the whole women's lane.", "caution": "Reclamation framing, never vanity, never before/after." }, { "slug": "/men", "title": "Men's hub", "lane": "metabolic", "angle": "Two doors: full-dose and the microdose route.", "caution": "Never describe either door by amount." }, { "slug": "/longevity", "title": "Longevity hub", "lane": "longevity", "angle": "Measurement before molecule.", "caution": "“Reverse aging” is banned outright." }, { "slug": "/recovery", "title": "Recovery hub", "lane": "recovery", "angle": "Where the demand is unsellable and honest.", "caution": "Every recovery peptide named here is gated. Status card only." }, { "slug": "/sexual-health", "title": "Sexual health hub", "lane": "sexual", "angle": "Plain clinical language beats every euphemism.", "caution": "PT-141 is gated; do not bring it into the hook." }, { "slug": "/bpc-157", "title": "BPC-157", "lane": "recovery", "angle": "The most-searched, least-sellable name in the category.", "caution": "Education only. No availability language in any form." }, { "slug": "/tb-500", "title": "TB-500", "lane": "recovery", "angle": "The second half of the recovery search volume.", "caution": "Education only. No availability language in any form." }, { "slug": "/ghk-cu", "title": "GHK-Cu", "lane": "longevity", "angle": "Topical and injectable are different regulatory pathways.", "caution": "Never merge the two forms into one status." }, { "slug": "/sermorelin", "title": "Sermorelin", "lane": "longevity", "angle": "A green-verdict molecule with real provenance.", "caution": "Withdrawn in 2008 for commercial reasons — say so accurately or not at all." }, { "slug": "/bpc-157-vs-tb-500", "title": "BPC-157 vs TB-500", "lane": "recovery", "angle": "The comparison the forums argue about, graded.", "caution": "Both are gated. Compare evidence, never access." }, { "slug": "/fda-tracker", "title": "The FDA Tracker", "lane": "recovery", "angle": "The dated regulatory board. The strongest link asset we have.", "caution": "Never summarise the board into one sentence." }, { "slug": "/fda-tracker-news", "title": "Tracker newsroom", "lane": "recovery", "angle": "Our dated record, with primary sources.", "caution": "Point at journalism; do not restate a verdict from memory." }, { "slug": "/fda-tracker-alerts", "title": "Status alerts", "lane": "recovery", "angle": "Get told when a verdict changes.", "caution": "Education and waitlist only." }, { "slug": "/knowledge-base", "title": "Knowledge Base", "lane": "longevity", "angle": "Fifty-four monographs, no dosing in any of them.", "caution": "No dosing fields exist. Never add one in your own summary." }, { "slug": "/stacks", "title": "Stacks", "lane": "longevity", "angle": "Combinations, graded, with the weak evidence labelled.", "caution": "A stack is not a prescription. Never publish one as instructions." }, { "slug": "/503a-vs-503b", "title": "503A vs 503B", "lane": "metabolic", "angle": "The pharmacy-category distinction, explained once, properly.", "caution": "Pure education. Nothing here may read as an offer." }, { "slug": "/how-to-spot-a-legit-provider", "title": "How to spot a legit provider", "lane": "metabolic", "angle": "A checklist that names nobody, including where we fail it.", "caution": "Do not turn it into a competitor attack." }, { "slug": "/peptides/how-we-grade", "title": "How we grade", "lane": "longevity", "angle": "Method, not outcome. The honest framing does the persuading.", "caution": "Evidence grade is never a traffic-light colour." } ], "widgets": [ { "id": "status_card", "name": "Live FDA status card", "route": "/embed", "does": "Drops a molecule's live two-signal status into a post. It re-reads the tracker on every page view, so the post can never go stale and can never overclaim — which is exactly why it beats a screenshot.", "fields": "Molecule · evidence grade · regulatory status pill · access verdict dot · last-synced date · source link. Two signals separated by a divider, each labelled. No price. No dose.", "needs_molecule": true, "snippet_example": "Peptós.LIFE FDA status: bpc-157\n" }, { "id": "page_card", "name": "Page card / link unit", "route": "/embed", "does": "A branded card for any of the 22 destinations: headline, one-line promise, the four proof cues, and the compliant CTA as a tagged sponsored link. Solves the creator writing their own CTA and drifting out of the perimeter.", "fields": "Headline · one-line promise · four proof cues · compliant CTA. No price, no availability field, no molecule status.", "needs_molecule": false, "snippet_example": "Peptós.LIFE — /metabolic-reset\n" }, { "id": "alert_badge", "name": "Status-change alert badge", "route": "/embed", "does": "A small inline badge that visibly flips when the tracker changes on a named molecule. Turns a one-time article into a recurring traffic asset: the reader comes back to a post that updates itself.", "fields": "Molecule · change state · date of change · optional link to /fda-tracker-alerts. No status prose, no availability field.", "needs_molecule": true, "snippet_example": "Peptós.LIFE status: bpc-157\n" }, { "id": "kb_search", "name": "Knowledge Base search box", "route": "/embed/search", "does": "An embeddable search over the 54-molecule Knowledge Base. The reader self-identifies the molecule they care about and lands on our monograph pre-qualified, with your tag attached site-wide. Highest-intent unit in the set.", "fields": "Query input · result title · evidence grade · both signals shown separately in the preview. No dosing fields exist in the index.", "needs_molecule": false, "snippet_example": "
\n" }, { "id": "monograph", "name": "Embeddable monograph", "route": "/embed/monograph/{slug}", "does": "The full monograph for any of the 54 molecules, on your domain, canonical back to ours. You get the content and the credit; we keep the SEO. What it is, how it works, who it is for, what it does not do, what is still unknown.", "fields": "What it is · how it works · who it is for · what it does not do · what is unknown · evidence grade · both signals · sources. No dosing fields exist and none may be added.", "needs_molecule": true, "snippet_example": "" } ], "catalysts": [ { "event": "Second PCAC peptide review", "window": "By end of Feb 2027", "publish_by": "Feb 1, 2027", "molecules": [ "ll-37", "ghk-cu-injectable", "dihexa", "melanotan-2" ], "angle": "What the second advisory batch is reviewing, and why a recommendation would still not be approval.", "destination": "/fda-tracker" }, { "event": "FDA Bulks List rulemaking decision", "window": "Projected 2027", "publish_by": "When the docket moves", "molecules": [ "bpc-157", "tb-500", "kpv", "mots-c", "semax", "epitalon" ], "angle": "The six recommended in July 2026 and what rulemaking actually has to do before anything changes.", "destination": "/fda-tracker-news" }, { "event": "Compounded GLP-1 policy movement", "window": "Ongoing through 2026–27", "publish_by": "Within 48h of any docket entry", "molecules": [ "semaglutide", "tirzepatide", "liraglutide" ], "angle": "What the shortage-exception pathway is, and why it is not the same as approval.", "destination": "/503a-vs-503b" }, { "event": "Anniversary of the July 2026 advisory vote", "window": "Jul 23–24, 2027", "publish_by": "Jul 9, 2027", "molecules": [ "bpc-157", "dsip" ], "angle": "One year on: six recommended, one declined, and what has and has not changed since.", "destination": "/fda-tracker-news" } ], "keyword_gaps": { "note": "Queries our 22 destinations already rank for, and the adjacent ones they do not. Write the complementary article and link in; do not compete with us for the same result.", "we_rank": [ "perimenopause weight gain", "why can't I lose weight at 45", "compounded semaglutide", "tirzepatide vs semaglutide", "NAD+ cost", "biological age test", "BPC-157 FDA status", "503A vs 503B", "PCAC peptide vote" ], "open_for_partners": [ "perimenopause strength training", "GLP-1 grocery list", "how to read a certificate of analysis", "questions to ask a telehealth prescriber", "menopause and sleep architecture", "protein intake during metabolic treatment", "what a compounding pharmacy inspection covers", "how FDA rulemaking actually works", "cost of a longevity panel" ] }, "changelog": [ { "date": "2026-08-15", "items": [ "Toolkit published: 22 destination kits, five widgets, the link builder and the compliance validator." ] }, { "date": "2026-07-26", "items": [ "Tracker resynced after the PCAC close. Every kit's adjacency warning re-derived; no kit copy changed, because no kit hard-codes a status." ] }, { "date": "2026-07-24", "items": [ "PCAC concluded: six of seven recommended, DSIP declined. All seven verdict dots remain amber.", "Retired every “decision expected” angle — the decision was advisory and rulemaking is pending." ] } ], "faq": [ { "q": "Do I need approval before I publish?", "a": "No. Everything on this page is pre-cleared. Use the hooks, the say-this lines and the compliant CTA as written and you are inside the perimeter. Write your own anchor text and the link builder will check it before you copy it." }, { "q": "Can I edit the hooks?", "a": "Yes, within the perimeter. The six rules on the compliance standard govern, not these exact sentences. If your edit adds an availability, legality, FDA-approval or dosing word, the validator will catch it — paste it in before you publish." }, { "q": "What am I actually being credited for right now?", "a": "A founding-list signup at /waitlist. Consults are not open, so nothing is transactable. Your tag holds site-wide for the cookie window, including on the tracker and Knowledge Base pages, and the flat CPA applies from first subscription once consults open." }, { "q": "Why is there no commission number on this page?", "a": "Because we have not set one, and publishing a rate we have not set would be the exact kind of claim this whole programme tells you not to make. Rates are set in your partner agreement." }, { "q": "The tracker changed a verdict. Do I have to update my old posts?", "a": "If you used a status embed, no — it re-reads the feed on every page view and updates itself. If you used a screenshot, yes, and this is the argument for using the embed. Subscribe at /fda-tracker-alerts and you will be told when something moves." }, { "q": "Can I write about BPC-157 at all?", "a": "Yes, extensively. You may explain what it is, what the evidence says, and exactly where its regulatory status stands. You may not say, imply, hint or joke that it can be obtained. The status card is the safest way to reference it, because it renders the current position rather than your memory of it." }, { "q": "Do the widgets need an API key?", "a": "No. They read public CC BY 4.0 feeds. Attribution and a link back are the licence terms. If the feed is unreachable the widget degrades to a plain branded link rather than rendering anything stale." }, { "q": "Can I run paid search?", "a": "Non-brand terms only. Bidding on our name, trademarks, or close misspellings ends the relationship. The full prohibited-traffic list is on the compliance standard." } ], "related": [ "https://peptos.life/partners", "https://peptos.life/partners/compliance", "https://peptos.life/fda-tracker", "https://peptos.life/embed", "https://peptos.life/for-ai.json" ] }